Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in hospitalized patients with COVID-19
IRCT20211203053263N2Phase 3Completed
- Sponsor
- Ilam University of Medical Sciences
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bosentan plus routine care with Placebo plus routine care (2 arms). Primary endpoint: Time to clinical improvement. Started Feb 2022; status: completed.
02
Drugs
bosentan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20211203053263N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211203053263N2.